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A B S T R A C T
Background
Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system (CNS) of
putative autoimmune aetiology. Early discrimination between multiple sclerosis (MS) and NMO
is important, as optimum treatment for both diseases may differ considerably. Recently, using
indirect immunofluorescence analysis, a new serum autoantibody (NMO-IgG) has been
detected in NMO patients. The binding sites of this autoantibody were reported to colocalize
with aquaporin 4 (AQP4) water channels. Thus we hypothesized that AQP4 antibodies in fact
characterize NMO patients.
Methods and Findings
Based on these observations we cloned human water channel AQP4, expressed the protein in
a eukaryotic transcription/translation system, and employed the recombinant AQP4 to
establish a new radioimmunoprecipitation assay (RIPA). Indeed, application of this RIPA
showed that antibodies against AQP4 exist in the majority of patients with NMO (n ¼ 37; 21
positive) as well as in patients with isolated longitudinally extensive transverse myelitis (n¼ 6;
six positive), corresponding to a sensitivity of 62.8% and a specificity of 98.3%. By contrast,
AQP4 antibodies were virtually absent in 291 other participants, which included patients with
MS (n¼144; four positive), patients with other inflammatory and noninflammatory neurological
diseases (n¼73; one positive), patients with systemic autoimmune diseases (n¼ 45; 0 positive),
and healthy participants (n ¼ 29; 0 positive).
Conclusions
In the largest series reported so far to our knowledge, we quantified AQP4 antibodies in
patients with NMO versus various other diseases, and showed that the aquaporin 4 water
channel is a target antigen in a majority of patients with NMO. The newly developed assay
represents a highly specific, observer-independent, and easily reproducible detection method
facilitating clinically relevant discrimination between NMO, MS, and other inflammatory
diseases.
The Editors’ Summary of this article follows the references.
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Introduction
Neuromyelitis optica (NMO, Devic syndrome) is a chronic
inflammatory demyelinating disease of the central nervous
system (CNS), mainly affecting the optic nerves and the spinal
cord [1–4]. It is still a matter of debate whether NMO
represents a disease entity in itself or whether it is a subform
of multiple sclerosis (MS). Like MS, NMO follows a relapsing–
remitting course in the majority of cases, but it usually leads
to more severe disability with impairment of functional
vision and/or loss of ambulation. Early differentiation of
NMO from MS and other inflammatory and demyelinating
diseases of the CNS—such as vasculitis, neuroborreliosis,
paraneoplastic neurological syndromes, or vitamin B12
deficiency—is highly desirable, as treatment options and
prognoses differ widely. However, such differentiation may
be difficult or even impossible owing to overlap in clinical
presentation and cerebrospinal fluid (CSF) and magnetic
resonance imaging (MRI) findings [5].
A serum autoantibody (called NMO-IgG) binding to CNS
microvessels, pia, subpia, and Virchow-Robin spaces was
recently identified in patients with NMO, using indirect
immunofluorescence [6]. The binding sites of this autoanti-
body were then reported to colocalize with aquaporin 4
(AQP4) water channels in mouse tissue of the brain, stomach
and kidney, generating the hypothesis of NMO as an
autoimmune channelopathy [7]. However, to date there has
been no systematic assessment of the occurrence and
frequency of AQP4 antibodies in NMO and other demyeli-
nating diseases. It is therefore still unclear whether antibodies
to AQP4 are specific for NMO and whether testing for these
antibodies may be useful for its diagnosis and its distinction
from diseases with similar clinical and neuroradiological
patterns, such as MS and other autoimmune diseases with
involvement of the CNS. The aim of our study was to assess
the frequency and specificity of antibodies to AQP4 in
patients with NMO, as well as relevant differential diagnoses,
by means of a newly developed radioimmunoprecipitation
assay (RIPA).
Methods
Patients
NMO patients meeting the diagnostic criteria proposed by
Wingerchuk et al. [1] and patients with longitudinally
extensive transverse myelitis (LETM) were recruited from
several neurology centers in Germany, Italy, and Great
Britain. Only patients for whom complete clinical and
paraclinical data were available (i.e., clinical course, labo-
ratory and CSF findings, MRI scans of the brain and spinal
cord) were eligible for participation in the study. Based upon
these selection criteria, 37 patients with NMO were included.
Spinal cord lesions extending over three or more vertebral
segments in MRI were present in all NMO patients, thus also
fulfilling the recently published revised criteria [8]. Another
six patients had isolated LETM (monophasic in three,
relapsing in three), with spinal lesions extending over three
or more segments, but without optic neuritis, and were thus
considered to be at ‘‘high risk of NMO’’ according to previous
proposals [9]. In addition, tests were carried out on serum
samples from 217 patients with miscellaneous inflammatory
and noninflammatory neurological disorders (among them
144 patients with MS fulfilling the panel criteria [10]), 45
patients with various rheumatological autoimmune diseases,
and 29 healthy participants included as controls (for
diagnostic categories see Table 1). Control participants were
recruited from the Cecilie-Vogt-Clinic for Molecular Neu-
rology in Berlin, Germany, the Clinic of Rheumatology in
Berlin, Germany, and the Institute of Clinical Neuroimmu-
nology in Munich, Germany. Serum testing in patients was
approved by the ethics committees of the participating
institutions.
RIPA
Following PCR-mediated amplification with suitable pri-
mer pairs, the cDNA-sequence of human aquaporin 4 (full-
length cDNA, amino acids 1–323) was cloned into a
pCITE4a vector (Novagen/Merck Biosciences, http://www.
merckbiosciences.com). In vitro transcription/translation
(IvTT) reactions were performed with the cDNA constructs
using a commercial system according to the manufacturer’s
instructions (Promega, http://www.promega.com). Briefly, 25
ll of rabbit reticulocyte lysate, 2 ll of reaction buffer, 1 ll
of amino acid mixture (without methionine), 1 ll of T7
polymerase, 3.5 ll of Redivue L-35S-methionine (GE Health-
care, http://www4.gelifesciences.com), 1 ll of RNasin (Cam-
brex BioScience, http://www.cambrex.com), and 1 lg of
template DNA were pipetted into a nuclease-free 1.5 ml
reaction tube. Nuclease-free water was added to a final
volume of 50 ll. After 90 min incubation at 30 8C,
unincorporated 35S-methionine was removed by gel filtra-
tion on a sephadex G-50 MicroSpin column (GE Health-
care). The percentage of incorporated 35S-methionine was
calculated using an LS1801 liquid scintillation counter
(Beckman, http://www.beckmancoulter.com). Quality and
concentration of labeled recombinant protein were ana-
lyzed by SDS-PAGE and autoradiography.
Recombinant 35S-methionine-AQP4 was diluted in 20 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 0.15% Tween-20, 100,000
KIE Trasylol, 10 mM benzamidine, and 0.1% bovine serum
albumin (working dilution) to yield an activity of 40,000 cpm
in 50 ll. Serum sample aliquots of 5 ll each were added to a
96-well plate, and 50 ll of 35S-methionine-AQP4 working
dilution were added to each well. Following incubation for 3
h at 4 8C on a shaker, 20 ll protein A Fractogel beads (Merck)
were added to each well. After incubation for 1 h at 4 8C the
reaction mixtures were transferred to a 0.65 lm Durapore 96-
well filter plate (Millipore, http://www.millipore.com). Un-
bound antigen was removed by vacuum filtration and washing
of the filter plates (30 times) with 100 ll of 20 mM Tris-HCl,
150 mM NaCl, and 0.05% Tween-20 each time. After drying
the plates overnight, 20 ll liquid scintillation mix Micro-
ScintO (PerkinElmer, http://www.perkinelmer.com) were
added to each well and the plates were counted using a
Topcount NXT 96-well liquid scintillation counter (Perki-
nElmer). All determinations were performed in duplicate. A
rabbit control antibody (rbAQP4) was prepared, using
standard immunization techniques, by immunizing a New
Zealand white rabbit with a human AQP4 peptide cocktail.
Mean cpm of five negative controls (healthy blood donors)
were used to calculate the antibody ratio (Ab-ratio) according
to a formula derived from Frey et al. [11]: Ab-ratio¼ sample
cpm / [mean negative cpm (five negative controls)þ f3 SD]3
10. Factor f was 3.041, calculated on the basis of a confidence
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interval of 97.5%. Cutoff was also calculated by means of the
equation suggested by Frey et al. [11]. All results with an Ab-
ratio .11 were considered positive. All samples were coded
with an alphanumerical ID and were analyzed blind. Testing
of the rabbit control antibody yielded an Ab-ratio of 133.2.
Statistics
Data processing (descriptive statistics: mean, range, and
standard deviation [SD]) and statistical analyses (antibody
positivity between groups: Fisher exact test; antibody ratios
between groups: Mann-Whitney test) were performed using
SPSS version 12.0 (http://www.spss.com).
Results
Establishment of a RIPA Based on Recombinant Human
AQP4
Using a eukaryotic transcription/translation system, we
expressed full-length human AQP4 protein in a cell-free
system, labeled with 35S, and established a RIPA. By perform-
ing titrations with several different volumes of AQP4 positive
and negative sera, we determined 5 ll to be the suitable
serum volume for routine analysis (Figure 1A). We also tested
two sera and the rabbit anti-AQP4 antibody (5 ll per sample)
at different concentrations of 35S-AQP4 and used the highest
activity of 35S-AQP4 for the subsequent investigations (Figure
1B). Determination of assay variation was performed for both
the rabbit serum rbAQP4 and the sera from nine individual
patients by screening ten samples from each donor either on
one single occasion (intra-assay variation) or on ten different
occasions (interassay variation). The mean intra-assay coef-
ficient of variation was 4.0% (SD 1.3%) and the mean
interassay coefficient of variation was 20.7% (SD 2.4%) across
the range of the assay. We also measured AQP4 antibodies
longitudinally in an LETM patient over a period of 1 y,
recording persistent antibody ratios between 23 and 28 (three
measurements) during the first 6 mo, and a subsequent
gradual decline to 16 under immunosuppression during the
following 6 mo while the total amount of IgG remained
unchanged (unpublished data).
Frequency of AQP4 Antibodies in Patient Populations
Next we tested sera from the different diagnostic catego-
ries. AQP4 antibodies were present (i.e., Ab-ratio . 11) in 21/
37 patients with NMO and in 6/6 of those with LETM, but in
only 5/291 control samples, including 4/144 with MS and 1/73
with other neurological diseases, 0/45 with rheumatological
diseases, and 0/29 healthy individuals (Fisher exact test, Chi-
square values ranging from 11.099 [NMO group versus optic
neuritis/optic neuropathy group, p ¼ 0.001] to 49.353 [NMO
versus MS with optic neuritis group], p , 0.001 for all other
tests) (Figure 2; Table 1). All four MS patients who tested
positive were female, had Ab-ratios ,15 and an onset age
.30 y, and had mainly clinical symptoms related to spinal
cord lesions, yet they did not meet the 1999 Wingerchuk
criteria for NMO. All four patients had oligoclonal bands and
none had spinal cord lesions extending over three or more
vertebral segments. The patient from the group of individuals
with other neurological diseases who tested positive in the
RIPA had carpal tunnel syndrome and showed an Ab-ratio
just above the cutoff. The results correspond to a sensitivity
of 56.8% and a specificity of 98.3% for the test in NMO, and
to 62.8% and 98.3%, respectively, if NMO and LETM patients
are considered together. The positive and negative likelihood
ratio reveal 33.03 and 0.44 for NMO, and 36.54 and 0.38 for
NMO and LETM patients together. Mean antibody ratios in
the NMO group were significantly higher than in the other
groups (Mann-Whitney test, z-values ranging from 2.736
[NMO group versus optic neuritis/optic neuropathy group, p
¼ 0.006] to 5.745 [NMO versus healthy controls], p , 0.001
for testing against all other groups). Different levels of
antibody binding may indicate the existence of different
affinity antibodies or different epitopes recognized in these
patients. All positive samples were negative when tested
against three control antigens: pemphigus vulgaris-associated
autoantigen desmoglein 3; M. Addison- and autoimmune
polyendocrine syndrome-associated steroid 21-hydroxylase;
and the myositis-associated autoantigen Ku 80, expressed in
the same vector system (unpublished data).
Table 1. Study Population and Proportion of AQP4-Positive Individuals in Ten Diagnostic Categories
Category Number Sex, Female/Male Age, y, Mean (Range) AQP4 Positive, Number AQP4 Positive, %
NMO 37 30/7 43.8 (12–72) 21 56.8
LETM 6 6/0 38 (22–57) 6 100
MS/ONþ 77 50/27 40.9 (18–61) 1 1.3
MS/ON 67 41/26 41.8 (21–65) 3 4.5
ON 11 9/2 41.6 (17–68) 0 0
MYL 15 8/7 40.3 (19–56) 0 0
OIND 20 12/8 49.4 (20–76) 0 0
OND 27 19/8 60.7 (18–87) 1 3.7
RD 45 36/9 52.3 (24–76) 0 0
HC 29 18/11 38.3 (15–61) 0 0
Total controls 291 193/98 45.6 (15–87) 5 1.7
Diagnostic categories: NMO, neuromyelitis optica; LETM, longitudinally extensive transverse myelitis extending over three or more vertebral segments in MRI (three monophasic, three
relapsing); MS/ONþ, multiple sclerosis with optic neuritis; MS/ON, multiple sclerosis without optic neuritis; ON, optic neuritis/optic neuropathy only (six monophasic, three relapsing, two
progressive optic atrophy of unknown aetiology); MYL, myelitis extending over fewer than three vertebral segments in MRI (11 monophasic, four relapsing); OIND, other inflammatory
neurological disorders and systemic disorders with neurological involvement (five vasculitis, one Wegener disease, two neuroborreliosis, one paraneoplastic encephalitis, one meningitis,
three chronic inflammatory demyelinating polyneuropathy, three systemic lupus erythematosus, one CNS lymphoma, two vitamin B12 deficiency, one zoster myelitis and radiculitis); OND,
other noninflammatory neurological diseases (carpal tunnel syndrome, radiculopathy, cerebral ischemia, vertigo); RD, rheumatological diseases without neurological involvement (11
rheumatoid arthritis, 16 Sjo¨gren syndrome, eight systemic lupus erythematosus, nine Wegener disease, one Bechterew disease); HC, healthy controls.
doi:10.1371/journal.pmed.0040133.t001
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Discussion
This study is, to our knowledge, the first to report on the
frequency of autoantibodies recognizing the AQP4 water
channel in patients with NMO and to evaluate its specificity
when compared to an adequate control group of different
patient populations and healthy individuals. Based on the
seminal observations of Lennon and colleagues suggesting
AQP4 as the target antigen in NMO [7], we cloned and
expressed human AQP4 to establish a quantitative radio-
immunoprecipitation assay. This novel approach allows
standardized high-throughput analysis. In our series of
patients with NMO and related disorders, we show that
antibodies to the AQP4 water channel are present in 63% of
patients with NMO or at high risk of the disease, but are
virtually absent in patients with MS and other inflammatory
and noninflammatory neurological diseases (5/217), as well as
in patients with rheumatological diseases and in healthy
controls (0/74). A methodological limitation here is the
moderate interassay variation coefficient in this type of assay,
although this can be overcome because of the very low intra-
assay variation coefficient and the fact that a high number of
samples can be measured simultaneously.
Recently, the general presence of a brain-specific autoanti-
body, designated NMO-IgG, was described in NMO and
determined in patients by indirect immunofluorescence [6].
This method of testing for NMO-IgG entails laborious and
cost-intensive preabsorption of patient sera, employing
blocking procedures in order to avoid unspecific binding
and false-positive results. Our detection assay for the specific
antibody AQP4 provides observer-independent. quantitative
data, and is therefore easily reproducible. It remains to be
shown whether all NMO-IgG-positive patients reported also
reveal reactivity against the AQP4 water channel.
In our study, antibodies to the AQP4 water channel were
sufficiently specific for NMO to allow differentiation fromMS
and other inflammatory neurological diseases. This finding is
of clinical relevance, as diagnosis of NMO based solely on
clinical, neuroradiological, and CSF findings may be difficult
or impossible. One question that has yet to be answered
satisfactorily is whether testing for AQP4 antibodies allows
diagnosis of NMO after the first event (i.e., first optic neuritis
or myelitis). Weinshenker et al. [9] recently demonstrated that
NMO-IgG seropositivity at the initial presentation of LETM
predicts relapse of myelitis or development of optic neuritis.
All six patients in our series with isolated LETM were positive
for antibodies to AQP4, a finding that supports the
hypothesis that LETM is an inaugural or limited form of
NMO [9]. We did not, however, detect the antibody in
patients with less extensive lesions, i.e., myelitis involving
fewer than three segments.
Finally, our findings suggest that testing for AQP4 anti-
bodies not only enables a reliable distinction to be made
between NMO and MS, but also facilitates differential
diagnosis concerning other autoimmune diseases affecting
the CNS. This ability to distinguish is particularly important
when patients presenting with myelitis have concomitant
Figure 2. Antibody Ratios Found in Patients with NMO and in Patients
with Relevant Differential Diagnoses or Healthy Controls
Each individual value represents the result from a single serum sample
tested twice with the AQP4 RIPA. Black horizontal bars represent mean.
The dashed horizontal line indicates the cutoff at an antibody ratio of 11.
Diagnostic categories: NMO, neuromyelitis optica; LETM longitudinally
extensive transverse myelitis; MS/ONþ, multiple sclerosis with optic
neuritis; MS/ON, multiple sclerosis without optic neuritis; ON, optic
neuritis; MYL, myelitis extending over fewer than three vertebral
segments on MRI; OIND, other inflammatory neurological disorders
and systemic disorders with neurological involvement (e.g., neuro-
borreliosis, chronic inflammatory demyelinating polyneuropathy; for
exact classification see legend for Table 1); OND, other noninflammatory
neurological diseases (e.g., carpal tunnel syndrome); RD, rheumatological
diseases without neurological involvement (for exact classification see
legend for Table 1); HC, healthy controls.
doi:10.1371/journal.pmed.0040133.g002
Figure 1. Characteristics of the Radioimmunoprecipitation Assay
(A) Titration curve to assess the optimal serum volumes. Five samples are
plotted: three positive (two NMO, one LETM) and two negative (one MS,
one healthy control [HC]). While positive sera bound up to 1,800 cpm of
35S-AQP4 with maximum binding at 2.5–5 ll, negative samples showed
no more than 300–400 cpm of precipitation at all serum volumes. Values
represent mean cpm of five independent measurements (error bars: SD).
(B) Immunoprecipitation at different concentrations of 35S-AQP4 (input
cpm ranging from 5,000 to 40,000) of a positive serum (NMO), a negative
serum (HC), and the rabbit serum rbAQP4 (5 ll per sample).
doi:10.1371/journal.pmed.0040133.g001
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serological findings suggesting systemic autoimmunity. Pos-
itive testing for autoantibodies (ANA, SS-A, SS-B) has been
reported in 38%–75% of patients with NMO [12,13], which
poses diagnostic challenges to clinicians in many cases. The
fact that sera positive for AQP4 antibodies did not show
reactivity in testing for the presence of autoantibodies
against three unrelated antigens using the same assay system
largely rules out nonspecific binding as a cause for anti-AQP4
positivity, and argues for the reliability and specificity of our
assay. The negative results in the rheumatological disease
group also argue against nonspecific binding of patients’ sera
to AQP4. Further studies will have to address the question of
whether AQP4 is the only target antigen in NMO, and
whether antibodies to AQP4 are pathogenic in NMO or a
mere epiphenomenon of the disease.
Accession Numbers
The Swiss-Prot (http://www.expasy.org/sprot) accession number for
aquaporin 4 is P55087.
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Editors’ Summary
Background. Neuromyelitis optica (NMO or Devic syndrome) is a rare
disease in which the immune system destroys the myelin (fatty material
that insulates nerve fibers so that the body and the brain can
communicate using electrical messages) in the optic nerve and spinal
cord. Myelin destruction (demyelination) in these parts of the central
nervous system (CNS) causes pain and swelling (inflammation) of the
optic nerve (optic neuritis) and spinal cord (myelitis). The resultant
disruption of communication along these nerves means that patients
with NMO experience temporary or permanent blindness in one or both
eyes that is preceded or followed by limb weakness or paralysis and loss
of bladder and bowel control. These two sets of symptoms can occur
many months apart and may happen once during a person’s lifetime or
recur at intervals. There is no cure for NMO, but corticosteroids or
plasmapheresis reduce inflammation during acute attacks and, because
NMO is an autoimmune disease (one in which the immune system
attacks the body’s own tissues instead of foreign organisms), long-term
immunosuppression may prevent further attacks.
Why Was This Study Done? There are many inflammatory/demyelinat-
ing diseases of the CNS with clinical symptoms similar to those of NMO.
It is particularly hard to distinguish between NMO and multiple sclerosis,
an autoimmune disease that involves widespread demyelination.
Neurologists need to make a correct diagnosis before starting any
treatment and usually use clinical examination and magnetic resonance
imaging (to detect sites of inflammation) to help them in this task.
Recently, however, a biomarker for NMO was identified. Many patients
with NMO make autoantibodies (proteins that recognize a component of
a person’s own tissues) called NMO-IgGs. These recognize aquaporin 4
(AQP4), a protein that allows water to move through cell membranes. It
is not known how often patients with NMO or other demyelinating
diseases make antibodies to AQP4, so it is unclear whether testing for
these antibodies would help in the diagnosis of NMO. In this study, the
researchers have developed a new assay for antibodies to AQP4 and
then quantified the antibodies in patients with NMO and other
demyelinating diseases.
What Did the Researchers Do and Find? The researchers made
radioactively labeled AQP4 in a test tube, then incubated samples of this
with serum (the liquid portion of blood), added small beads coated with
protein A (a bacterial protein that binds to antibodies) and allowed the
beads to settle. The amount of radioactivity attached to the beads
indicates the amount of antibody to AQP4 in the original serum. The
researchers used this radioimmunoprecipitation assay to measure
antibodies to AQP4 in sera from 37 patients with NMO and from six
with another neurological condition, longitudinally extensive transverse
myelitis (LETM), which is characterized by large demyelinated lesions
across the width of the spinal cord but no optic neuritis; these patients
often develop NMO. They also measured antibodies to AQP4 in the sera
of nearly 300 other people including patients with multiple sclerosis,
other neurological conditions, various autoimmune diseases, and healthy
individuals. Nearly two-thirds of the patients with NMO and all those
with LETM made antibodies against AQP4; very few of the other study
participants made these antibodies. In particular, only four of the 144
patients with multiple sclerosis made AQP4 antibodies.
What Do These Findings Mean? These findings indicate that testing for
antibodies to AQP4 could help neurologists distinguish between NMO
and multiple sclerosis and between NMO and other demyelinating
diseases of the CNS. In addition, the new radioimmunoprecipitation
assay provides a standardized, high-throughput way to quantitatively
test for these antibodies, whereas the indirect immune fluorescence
assay for measurement of unspecific NMO-IgG is observer-dependent
and nonquantitative. Although these findings need to be confirmed in
more patients and the assay’s reliability demonstrated in different
settings, the measurement of antibodies to AQP4 by radioimmunopre-
cipitation may become a standard part of the differential diagnosis of
NMO. Additional research will determine whether AQP4 is the only
protein targeted by autoantibodies in NMO and whether this targeting is
a critical part of the disease process.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0040133.
 US National Institute of Neurological Disorders and Stroke has
information for patients who have neuromyelitis optica, transverse
myelitis, and multiple sclerosis
 The Transverse Myelitis Association offers information and useful links
for patients and their carers about transverse myelitis and neuromye-
litis optica (in several languages, including English and Spanish)
 Mayo Clinic information for patients on Devic’s syndrome
 Medline Plus encyclopedia pages discuss autoimmune disorders (in
English and Spanish)
 A brief overview of aquaporins is available from the University of
Miami
 The American MS Society has information on MS
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